Sobi's Long-Serving CEO Guido Oelkers to Step Down
The board has started a successor search as Oelkers stays on through January 2027 and Sobi reports 2,000 employees worldwide.
- On Monday, Swedish Orphan Biovitrum announced CEO Guido Oelkers, Ph.D., will step down to join BioNTech SE as Chief Executive Officer, with his transition effective by February 1, 2027.
- Oelkers has led Sobi since 2017, quadrupling annual revenues to SEK 28 billion while strengthening the rare disease portfolio. He will remain active in his CEO role until end of January 2027.
- Sobi Chairman David Meek thanked Oelkers for "nearly 10 years of dedication and leadership," while Oelkers stated, "Leading Sobi has been a privilege, and I am proud of what we have accomplished together."
- The Sobi Board of Directors has launched an immediate search for a successor to ensure "continuity and a smooth transition for our business and our employees," per Meek.
- Succeeding Prof. Ugur Sahin, M.D., Oelkers will join BioNTech's Management Board to support the company's strategic evolution into a multi-product organization focused on rare diseases.
20 Articles
20 Articles
The pharmaceutical manager Guido Oelkers is due to lead the vaccine manufacturer Biontech from next year.
In the Corona pandemic, Biontech becomes one of the biopharma addresses in Germany. The Mainz-based company, however, is most recently in a state of crisis. A new boss could give an impulse. Guido Oelkers has now found it, which is primarily intended to boost the US business.
BioNTech has announced the appointment of Guido Oelkers, current head of Swedish Orphan Biovitrum (Sobi), to replace co-founder Ugur Sahin as its next CEO. Exclusive content for subscribers. For full access, follow the link to the article and register.
It is not yet clear which development the vaccine specialist Biontech is taking after the departure of its founders. After all, it is now clear who follows Ugur Şahin on the head chair.
Guido Oelkers succeeds BioNTech founder Uğur Şahin, who wants to leave the vaccine manufacturer together with co-founder Özlem Türeci by the end of 2026.
Coverage Details
Bias Distribution
- 46% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
